Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer

Launched by FEIXUE SONG · Mar 11, 2024

Keywords

ClinConnect Summary

This clinical trial is studying whether combining electroacupuncture with a standard anti-nausea medication can better help breast cancer patients who are experiencing nausea and vomiting due to chemotherapy. Electroacupuncture involves using small electrical currents on acupuncture needles to stimulate certain points on the body, which may enhance the effectiveness of traditional anti-nausea drugs. The goal is to find out if this combination can provide better relief for patients undergoing particularly strong chemotherapy treatments.

To be eligible for this trial, participants should be between 18 and 75 years old and have early-stage breast cancer. They must be receiving a specific type of chemotherapy known to cause nausea and vomiting. However, those who have certain medical conditions, are scheduled for radiation therapy soon, or have experienced severe nausea or vomiting recently may not qualify. Participants can expect to receive both the electroacupuncture treatment and the anti-nausea medication, and the study aims to improve their overall comfort during chemotherapy. It's an exciting opportunity for patients looking for additional support in managing the side effects of their treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients aged 18 to 75 years, inclusive, from any nationality.
• • 2. Patients diagnosed with early-stage breast cancer.
• • 3. Eastern Cooperative Oncology Group performance status ranging from 0 to 2.
• • 4. All patients must undergo highly emetogenic chemotherapy (HEC).
• • 5. Adequate organ function.
• • 6. Adequate contraception required for premenopausal women.
• Exclusion Criteria:
• • 1. Scheduled to undergo chemotherapy between days 2 to 4 following HEC.
• • 2. Received or is planned to receive abdominal radiation therapy within 1 week before Day 1 in cycle 1.
• • 3. Significant medical or psychological conditions.
• • 4. Presents with symptomatic primary or metastatic central nervous system malignancy causing nausea and/or vomiting.
• • 5. Experiencing ongoing vomiting or nausea of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE).
• • 6. Any known allergies to the study drug, antiemetics, or dexamethasone.
• • 7. Patients who have fear of electroacupuncture stimulation or are allergic to stainless steel needles.
• • 8. Received acupuncture treatments for any conditions within 8 weeks prior to HEC.